Universität zu Köln

Doescher, J., Busch, C. -J., Wollenberg, B., Dietz, A., Wuerdemann, N., Schuler, P., Hoffmann, T. K. and Laban, S. (2019). Immunotherapy for head and neck cancer Highlights of the 2019 ASCO Annual Meeting. HNO, 67 (12). S. 905 - 912. NEW YORK: SPRINGER. ISSN 1433-0458

Full text not available from this repository.

Abstract

Background In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were a highlight at this year's meeting of the American Society of Clinical Oncology (ASCO). Materials and methods All abstracts and presentations on immunotherapy of head and neck tumors presented at ASCO 2019 were evaluated for relevance and the most interesting studies were summarized. Results The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU). The EAGLE study on durvalumab & x202f;+/- tremelimumab in second-line therapy did not demonstrate any improvement in response rates or overall survival compared to standard therapy. In addition, several new immunotherapeutic approaches and combinations were presented. Conclusion The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Doescher, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Busch, C. -J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wollenberg, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietz, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wuerdemann, N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schuler, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, T. K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Laban, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-130932
DOI:	10.1007/s00106-019-00761-8
Journal or Publication Title:	HNO
Volume:	67
Number:	12
Page Range:	S. 905 - 912
Date:	2019
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1433-0458
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SQUAMOUS-CELL CARCINOMA; RECURRENT; CISPLATIN; CETUXIMAB Multiple languages Otorhinolaryngology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13093